Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in Lymphoma

Video

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

Ira Braunschweig, MD, director, Stem Cell Transplant Program, clinical program director, Hematologic Malignancies, Montefiore Medical Center, associate professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

Despite the encouraging responses that have been observed with CAR T-cell therapy in lymphoma, several toxicities ​can arise with these products.

However, data suggests that ​administration of the immunosuppressive agent tocilizumab (Actemra) at fever onset could help mitigate some of the adverse effects, such as cytokine release syndrome, says Braunschweig. Notably, this agent will not abrogate the anti-tumor effect of the cellular therapy. 

Furthermore, ​data have shown that ​early steroid use may mitigate neurotoxicity, Braunschweig adds. ​Using steroids, which kill lymphocytes, may seem counterintuitive as CAR T cells are lymphocytes. However,​ steroids appear to mitigate neurotoxicity without alter​ing the mechanism of​ action of the​ CAR T-cell therapy.

Utilizing steroids early may eliminate the risk of confusion or, in severe cases, coma, among patients with lymphoma who receive CAR T-cell therapy, Braunschweig concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.